University General Hospital Attikon

At University General Hospital Attikon, clinical trials in cardiovascular diseases and nutritional and metabolic disorders focus on conditions such as heart failure, atrial fibrillation, myocardial infarction, hypertension, obesity, and type 2 diabetes. These studies are designed to test new treatment options, reduce major cardiovascular events, and improve long-term disease control.

• Testing therapies for heart failure and prevention of hospitalization
• Evaluating treatments to lower risk in atrial fibrillation and stroke
• Studying approaches for type 2 diabetes, obesity, and related cardiovascular risk

The site also contributes to research on inflammation-linked cardiovascular disease, reflecting a broad interest in improving both symptom control and prevention.

A major part of the research portfolio at this Athens site centers on neoplasms and hemic and lymphatic diseases. Trials include lung cancer, breast cancer, urothelial cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, and myelodysplastic syndromes, with the goal of improving survival, delaying progression, and refining cancer care.

• Assessing new therapies for advanced solid tumors and metastatic disease
• Evaluating treatment effectiveness in lymphoma, leukemia, and myelofibrosis
• Studying adjuvant and targeted approaches in breast, lung, and urothelial cancers

The oncology program spans both common and rare cancers, showing a strong emphasis on expanding treatment options across multiple disease settings.

The site conducts extensive research in immune system diseases, connective tissue diseases, and musculoskeletal diseases. Key conditions include rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, hidradenitis suppurativa, bullous pemphigoid, and myasthenia gravis. These trials aim to improve symptom relief, control inflammation, and assess the safety and effectiveness of emerging therapies.

• Testing new treatments for autoimmune and inflammatory skin diseases
• Evaluating disease control in rheumatoid arthritis and lupus
• Studying therapies for myasthenia gravis and other immune-mediated conditions

This research area reflects a broad commitment to chronic immune-driven diseases that can significantly affect daily function and quality of life.

Clinical research in nervous system diseases and mental disorders includes studies in multiple sclerosis, epilepsy, stroke, Alzheimer’s disease, cognitive impairment, schizophrenia, and major depressive disorder. The purpose of these trials is to explore better symptom management, prevent worsening disease, and support improved neurological and mental health outcomes.

• Evaluating therapies for relapsing multiple sclerosis and other demyelinating disorders
• Studying treatments for epilepsy and post-stroke recovery
• Assessing new approaches for Alzheimer’s-related behavioral and cognitive symptoms

The program combines chronic neurological care with research into brain health, memory disorders, and psychiatric conditions.

Trials in bacterial infections, virus diseases, and respiratory tract diseases address COVID-19, sepsis, pneumonia, candidemia, urinary tract infections, and other serious hospital-based infections. Research here is focused on improving diagnosis, guiding treatment decisions, and evaluating therapies that may reduce complications and mortality.

• Testing treatments for sepsis and severe systemic infection
• Evaluating therapies for COVID-19 and other acute respiratory infections
• Studying better management of pneumonia, cUTI, and invasive fungal infections

The site’s work in this area supports care for both community-acquired and hospital-acquired infections, especially in patients with complex medical needs.

Another important focus is digestive system diseases, kidney diseases, and related internal medicine conditions. Trials involve ulcerative colitis, Crohn’s disease, eosinophilic esophagitis, chronic kidney disease, IgA nephropathy, and glomerulonephritis. These studies are intended to improve disease control, reduce flares, and evaluate new approaches for chronic organ-specific illness.

• Assessing treatments for inflammatory bowel disease
• Studying therapies for kidney inflammation and progressive renal disease
• Evaluating options for chronic digestive and immune-mediated conditions

The research profile shows strong overlap between gastroenterology, nephrology, and systemic inflammatory disease management.

The remaining portfolio includes eye diseases, skin and connective tissue diseases, and other complex conditions such as glaucoma, age-related macular degeneration, atopic dermatitis, psoriasis, prurigo nodularis, and selected congenital and rare diseases. These trials are generally aimed at improving disease monitoring, symptom relief, and the effectiveness of targeted therapies.

• Evaluating new approaches for retinal and glaucoma care
• Studying treatments for chronic skin inflammation and itch-related disorders
• Including selected rare genetic and pediatric conditions

This broad mix of studies highlights the hospital’s role in addressing both common chronic illnesses and less frequent specialized disorders.